Recruitment and consent
Cancer
BLOOD, PEDIATRIC SOLID TUMOR, CANCER
This protocol may be abstracted into a plain language announcement posted on NIH websites and on NIH social media platforms. Participant retention is completed through good relationships between the treating physician, research team, participant and family.Participants will be offered co-enrollment on protocol 10-C-0086: Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies.Participants will be offered co-enrollment on protocol NCI-11-C-0242: Collection of Blood from Patients with Cancer for Analysis of Genetic Differences in Drug Disposition.The informed consent document will be provided as a physical or electronic document to the participant or consent designee(s) as applicable for review prior to consenting. A designated study investigator will carefully explain the procedures and tests involved in this study, and the associated risks, discomforts and benefits. In order to minimize potential coercion, as much time as is needed to review the document will be given, including an opportunity to discuss it with friends, family members and/or other advisors, and to ask questions of any designated study investigator. A signed informed consent document will be obtained prior to entry onto the study. Consent will be documented with required signatures on the physical document (which includes the printout of an electronic document sent to participant) or as described below, with a manual (non-electronic) signature on the electronic document. When required, witness signature will be obtained similarly as described for the investigator and participant.